Skip to main content
. 2023 Jul 21;7:70. doi: 10.1038/s41698-023-00417-5

Fig. 7. Erdafitinib and quisinostat are synergistic in BC cells with FGFR3 activating mutations.

Fig. 7

a Schematic diagram of FGFR3 S249 mutation. Red arrowhead represents the position of S249C in FGFR3. b MacSynergy II calculation (95% confidence interval) of the synergy between erdafitinib and quisinostat in UM-UC-14 cells, which is a BC cell line with FGFR3 S249C mutation. Cells were treated by different concentrations of erdafitinib and/or quisinostat for 3 days. And cell viabilities were determined by WST-1 assay and normalized to DMSO control. Synergistic inhibition was calculated by MacSynergy II. Synergistic inhibition above 0 means synergy, equal to 0 indicates additivity, and below 0 suggests antagonism. c Cell viability of UM-UC-14 cells by the treatment of erdafitinib and/or quisinostat. Cells were treated by erdafitinib and/or quisinostat for 3 days. And cell viabilities were determined by WST-1 assay and normalized to DMSO control. Data were plotted as mean ± standard deviation from three biological replicates and statistics were calculated by one-way ANOVA (****p < 0.0001). 2.5E, 2.5 nM erdafitinib; 2.5Q, 2.5 nM quisisnostat. d Western blots showing the FGFR3 and HDGF expression level with or without quisinostat treatment in UM-UC-14 cells. Cells were treated by quisisnostat for 2 days and then harvested for western blotting. β-actin (ACTB) was used as standard loading control. 10/25/50Q, 10/25/50 nM quisisnostat.